Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

ABSTRACT:

Background

The clinical relevance of detecting minority drug-resistant human immunodeficiency virus type 1 (HIV-1) variants is uncertain.

Methods

To determine the effect of pre-existing minority nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant variants on the risk of virologic failure, we reanalyzed a case-cohort substudy of efavirenz recipients in AIDS Clinical Trials Group protocol A5095. Minority K103N or Y181C populations were determined by allele-specific polymerase chain reaction in subjects without NNRTI resistance by population sequencing. Weighted Cox proportional hazards models adjusted for recent treatment adherence estimated the relative risk of virologic failure in the presence of NNRTI-resistant minority variants.

Results

The evaluable cas

SUBMITTER: Paredes R 

PROVIDER: S-EPMC2825289 | biostudies-literature | 2010 Mar

REPOSITORIES: biostudies-literature